2082eTiP COPERNICUS: A multinational pragmatic phase II trial of subcutaneous (SC) amivantamab (Ami) in common EGFR-mutated (cEGFRm) NSCLC
Year: 2025
Type: article
Source: Annals of Oncology
Authors: B. Halmos, N. Florez, S.B. Goldberg, W. Iams, X. Le, T.A. Leal, D. Nguyen, L.E. Raez, J.W. Riess, J. Sabari, D. Bjork, N. Stigger, A.R. Minchom, K. Xia, P. Cifuentes, F. Shanoon, J. Penton, A. Hulten, M.L. Johnson
Institutions: Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, Harvard University, Dana-Farber Cancer Institute, Yale Cancer Center, Yale University, Tennessee Oncology, The University of Texas MD Anderson Cancer Center, Emory University, Winship Cancer Institute, City of Hope, UC Davis Comprehensive Cancer Center, NYU Langone Health, LUNGevity Foundation, Institute of Cancer Research, Johnson & Johnson (United States), Johnson & Johnson (United Kingdom), Sarah Cannon
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: Johnson and Johnson
OpenAlex ID: W4415942073
FWCI:
Cites:
Cited by:
Related to: